13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001009258
Total reported value
$9.6B
$9.6B
82 檔
33.4%
According to the latest 13F quarterly dataset, Deerfield Management Company, L.p. managed an equity portfolio of $9.6B at the end of Q1 2026, spanning 82 distinct U.S. exchange-listed positions.
In Q1 2026, Deerfield Management Company, L.p. adopted a defensive or profit-taking posture, trimming 9 positions and completely liquidating 80 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 20.85% | +1.37% | — | |
| 2 | BKD 3.5 10-15-29Bond | Brookdale Senior Living | Bond | 5.96% | +0.15% | — | |
| 3 | COGT | Cogent Biosciences Inc | Stock-Other | 4.11% | -2.09% | — | |
| 4 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.66% | -0.30% | +6.64% | |
| 5 | VTRS | Viatris Inc | Stock-Healthcare | 3.22% | +0.13% | — | |
| 6 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.20% | -0.62% | +7.28% | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.64% | +2.03% | -20.65% | |
| 8 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | Bond | 2.47% | -2.47% | EXIT | |
| 9 | ARWR 0 01-15-32Bond | Arrowhead Research CORP | Bond | 2.44% | +0.07% | — | |
| 10 | CELC | Celcuity Inc | Stock-Other | 2.31% | -0.73% | — | |
| 11 | CNC | Centene CORP | Stock-Healthcare | 2.29% | +0.99% | -8.23% | |
| 12 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.89% | -0.76% | +16.34% | |
| 13 | BKD | Brookdale Senior Living Inc | Stock-Other | 1.88% | +0.07% | — | |
| 14 | VERA | Vera Therapeutics Inc | Stock-Other | 1.77% | -0.02% | -8.32% | |
| 15 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.75% | -0.11% | — | |
| 16 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.69% | -0.12% | +4.86% | |
| 17 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.64% | -1.04% | +79.51% | |
| 18 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.64% | +0.81% | +29.60% | |
| 19 | AHCO | Adapthealth CORP | Stock-Other | 1.61% | -0.36% | — | |
| 20 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.61% | -0.10% | +2.40% | |
| 21 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 1.25% | +0.14% | — | |
| 22 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.16% | +0.02% | -14.17% | |
| 23 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 1.15% | -1.15% | EXIT | |
| 24 | INDV | Indivior Pharmaceuticals Inc | Stock-Other | 1.11% | -0.40% | — | |
| 25 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.11% | -0.09% | +198.09% | |
| 26 | IONS 1.75 06-15-28Bond | Ionis Pharmaceuticals In | Bond | 1.07% | -0.10% | — | |
| 27 | PHVS | Pharvaris N.V. | Stock-Other | 1.04% | +0.18% | — | |
| 28 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.04% | -0.18% | — | |
| 29 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.02% | +0.35% | +42.65% | |
| 30 | ALHC 4.25 11-15-29Bond | Alignment Healthcare | Bond | 1.01% | +0.07% | — | |
| 31 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.01% | +0.13% | — | |
| 32 | PFE | Pfizer Inc | Stock-Healthcare | 1.01% | -0.25% | — | |
| 33 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.95% | -0.95% | EXIT | |
| 34 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.94% | -0.94% | EXIT | |
| 35 | SVRA | Savara Inc | Stock-Other | 0.87% | — | — | |
| 36 | ZBIO 2.5 04-01-32Bond | Zenas Biopharma Inc | Bond | 0.79% | +0.05% | — | |
| 37 | EHABUSD | Enhabit Inc | Stock-Other | 0.79% | -0.79% | EXIT | |
| 38 | NEO 0.25 01-15-28Bond | Neogenomics Inc | Bond | 0.79% | -0.66% | — | |
| 39 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.78% | +1.19% | — | |
| 40 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 0.74% | -0.05% | — | |
| 41 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.74% | +0.13% | — | |
| 42 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.71% | -0.08% | — | |
| 43 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.70% | -0.08% | — | |
| 44 | NVST | Envista Holdings CORP | Stock-Healthcare | 0.66% | -0.05% | -3.09% | |
| 45 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.60% | +0.46% | -28.94% | |
| 46 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.57% | — | +30.02% | |
| 47 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.57% | +0.23% | — | |
| 48 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.55% | -0.55% | EXIT | |
| 49 | CERT | Certara Inc | Stock-Other | 0.53% | -0.02% | — | |
| 50 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.52% | -0.13% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XENE | Xenon Pharmaceuticals Inc | +0.8% | +198.09% | Add |
| 2 | TNGX | Tango Therapeutics Inc | +0.7% | +42.65% | Add |
| 3 | UTHR | United Therapeutics CORP | +0.6% | +7.28% | Add |
| 4 | BKD 3.5 10-15-29Bond | Brookdale Senior Living | +0.5% | — | Unchanged |
| 5 | DAWNGBX | Day One Biopharmaceuticals I | +0.5% | — | Unchanged |
| 6 | ACHC | Acadia Healthcare Co Inc | +0.4% | — | Unchanged |
| 7 | LRMR | Larimar Therapeutics Inc | +0.4% | +16.34% | Add |
| 8 | BKD | Brookdale Senior Living Inc | +0.3% | — | Unchanged |
| 9 | PRAX | Praxis Precision Medicines I | +0.3% | +6.64% | Add |
| 10 | BCRX | Biocryst Pharmaceuticals Inc | +0.3% | +4.86% | Add |
| 11 | EHABUSD | Enhabit Inc | +0.2% | — | Unchanged |
| 12 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | +0.2% | — | Unchanged |
| 13 | AHCO | Adapthealth CORP | +0.2% | — | Unchanged |
| 14 | CELC | Celcuity Inc | +0.1% | — | Unchanged |
| 15 | BLTE | Belite Bio Inc - Adr | +0.1% | +30.02% | Add |
| 16 | MNPR | Monopar Therapeutics Inc | +0.1% | +89.82% | Add |
| 17 | LNTH | Lantheus Holdings Inc | 0% | — | Unchanged |
| 18 | NVST | Envista Holdings CORP | 0% | -3.09% | Trim |
| 19 | COGT | Cogent Biosciences Inc | 0% | — | Unchanged |
| 20 | VTRS | Viatris Inc | 0% | — | Unchanged |
| 21 | CGEM | Cullinan Therapeutics Inc | 0% | — | Unchanged |
| 22 | ALEC | Alector Inc | 0% | — | Unchanged |
| 23 | PHGE | Biomx Inc | 0% | +0.00% | Add |
| 24 | FHTX | Foghorn Therapeutics Inc | — | +20.42% | Add |
| 25 | ANNX | Annexon Inc | — | — | Unchanged |
| 26 | TOIIW | Oncology Institute Inc Cw-22 | — | — | Unchanged |
| 27 | HUM | Humana Inc | — | — | Unchanged |
| 28 | EW | Edwards Lifesciences CORP | — | — | Unchanged |
| 29 | QSIAW | Quantum-si Inc -cw27 | — | — | Unchanged |
| 30 | MYGN | Myriad Genetics Inc | — | — | Unchanged |
| 31 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 32 | PMVP | Pmv Pharmaceuticals Inc | — | — | Unchanged |
| 33 | LEGN | Legend Biotech Corp-adr | 0% | +29.60% | Add |
| 34 | KYMR | Kymera Therapeutics Inc | 0% | — | Unchanged |
| 35 | ✓ | Newamsterdam Pharma Company | 0% | — | Unchanged |
| 36 | IRON | Disc Medicine Inc | 0% | +28.53% | Add |
| 37 | TOI | Oncology Institute Inc/the | 0% | — | Unchanged |
| 38 | CMPX | Compass Therapeutics Inc | 0% | — | Unchanged |
| 39 | IMCR 2.5 02-01-30Bond | Immunocore Holdings | 0% | — | Unchanged |
| 40 | NEO 0.25 01-15-28Bond | Neogenomics Inc | 0% | — | Unchanged |
| 41 | KYTX | Kyverna Therapeutics Inc | 0% | — | Unchanged |
| 42 | STOK | Stoke Therapeutics Inc | 0% | — | Unchanged |
| 43 | LIVN 2.5 03-15-29Bond | Livanova PLC | 0% | — | Unchanged |
| 44 | TSHA | Taysha Gene Therapies Inc | -0.1% | — | Unchanged |
| 45 | SION | Sionna Therapeutics Inc | -0.1% | — | Unchanged |
| 46 | ALNY | Alnylam Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 47 | PHVS | Pharvaris N.V. | -0.1% | — | Unchanged |
| 48 | CDNA | Caredx Inc | -0.1% | — | Unchanged |
| 49 | VCYT | Veracyte Inc | -0.1% | — | Unchanged |
| 50 | BIO | Bio-rad Laboratories-a | -0.1% | — | Unchanged |
According to official SEC Form 13F filings, Deerfield Management Company, L.p. reported a total U.S. public equity portfolio value of $9.6B across 82 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, BKD 3.5 10-15-29, COGT) accounted for 33.4% of total reported equity market value during Q1 2026.
Top New Position Initiated
ARWR 0 01-15-32
市值: $207.2M
Top Position Liquidated / Trimmed
INDV
前期市值: $121.7M
During Q1 2026, Deerfield Management Company, L.p.'s top holdings by market value included NUVL (20.9%)、BKD 3.5 10-15-29 (6.0%)、COGT (4.1%). The largest single position, NUVL, represented 20.9% of total portfolio value.
In Q1 2026, Deerfield Management Company, L.p. made 116 total portfolio adjustments, initiating 12 new buys, adding to 15 positions, trimming 9 holdings, and fully liquidating 80 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.